Reputations for Sale ? BMJ-BBC-Panorama-Seroxat/ Paxil
BBC-Panorama–third in a series: The Secrets of Seroxat. "In the interests of patients and professional integrity" is to show those who have sold their reputations "intolerance and exposure."
Canadian Study: SSRI Increase Bone Fracture Risk
"Daily use of SSRIs was also associated with a four per cent reduction in bone mineral density of the hip and 2.4 per cent of the lower spine, the study found."
YouTube Videos RE: Antidepressants
The video, "Zyprexa Drug Rep," was posted on YouTube on Dec. 18. When AHRP publicized its (Jan 4) there were something on the order of 38 hits. Since the Infomail was posted on the AHRP website and blog (http://ahrp.blogspot.com the number has reached: 1,429.
Public Testimonies at FDA-SSRI-Suicidality Hearings, Dec. 13, 2006
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
Eli Lilly Documents Show Risks of Zyprexa were deliberately played down_NYT
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
MEDIA ALERT: Drug Victim advocates and Expert Scientists and Physicians
Expert Scientists, Psychiatrists, a Primary Care Physician, a Leading Attorney, will shed light on FDA’s Review of selected data Re: Antidepressants and Adult Suicidality One day prior to FDA’s Advisory Committee Hearing, December 13.
Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry?
Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry? Fri, 19 Dec 2003 Carl Elliott is a clear eyed academic who teaches bioethics at the University of Minnesota . He is currently a visiting associate professor at School of Social Sciences at the Institute for Advanced Study at Princeton….
ACNP Summary Report Criticized as "Junk Science"
ACNP Summary Report Criticized as “Junk Science” Sun, 25 Jan 2004 related links: Reply to ACNP Report – Jonathan Leo, Ph.D. FDA Sham Conflicts of Interest Policy Most of the National press coverage of the controversy swirling around the claims and counter claims about drug suicidal obsessive thinking and behavior…
Dr. Wolpe’s Accusations and Dr. Healy’s Response
Dr. Wolpe’s Accusations and Dr. Healy’s Response —–Original Message—– From: Paul Root Wolpe Sent: Tuesday, October 28, 2003 4:30 PM To: VERACARE Subject: Re: Ethics of U Penn surgical “drug implant” experiment Vera, We will have to agree to disagree, so this will be my last email on this. A…
UK issues ban on second SSRI antidepressant for children
UK issues ban on second SSRI antidepressant for children Sun, 21 Sep 2003 The UK Observer reports (below) that although antidepressant drugs of the SSRI class have not been approved for children, last year doctors (who are unaware of the severe risks associated with SSRIs) wrote 170,000 prescriptions of antidepressants…
Op Ed: Psychiatry on the Ropes–WP / Evidence-based Psychiatry– Multi-Discipline Conference_ NYC
Op Ed: Psychiatry on the Ropes–WP / Evidence-based Psychiatry– Multi-Discipline Conference_ NYC Mon, 4 Oct 2004 An Op Ed article in The Washington Post by Shannon Brownlee (below) nails the elite procurers of psychotropic drugs who have long denied the ominous signals of drug-induced harm: “You’d think the psychiatric research…
Bioethics Debate: Ethics of U Penn surgical “drug implant” experiment
Bioethics Debate: Ethics of U Penn Surgical “Drug Implant” Experiment This debate between AHRP President, Vera Sharav and Bioethicist, Paul Root Volpe, Ph.D., University of Pennsylvania, was prompted by an October 7 infomail. The reasons for AHRP’s opposition to drug implants for psychiatric patients are explained here: https://ahrp.org/ahrpspeaks/drugimplant1103.php —–Original Message—–…